-

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), announced today that Joe Morrissey, Interim Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3rd, 2025 at 10:00 a.m. ET.

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at https://www.organon.com/investor-relations/events-and-presentations/.

About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets.

Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.

Contacts

Media Contacts:

Felicia Bisaro
(646) 703-1807

Kate Vossen
(732) 675-8448

Investor Contacts:

Jennifer Halchak
(201) 275-2711

Renee McKnight
(551) 204-6129

Organon & Co.

NYSE:OGN
Details
Headquarters: Jersey City, New Jersey, USA
CEO: Joseph Morrissey
Employees: 10,000
Organization: PUB

Release Summary
Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3.
Release Versions

Contacts

Media Contacts:

Felicia Bisaro
(646) 703-1807

Kate Vossen
(732) 675-8448

Investor Contacts:

Jennifer Halchak
(201) 275-2711

Renee McKnight
(551) 204-6129

Social Media Profiles
More News From Organon & Co.

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon presents results from new VTAMA sub-analysis showing early and consistent improvement in atopic dermatitis patient-reported sleep subdomains....

Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Dru...

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2025 and Full Year 2025 earnings results, ending December 31, 2025....
Back to Newsroom